Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
OSCA 12-Month Evaluation
29
2025.05
Kangstem Biotech has reported that a single injection of its knee osteoarthritis treatment OSCA demonstrated sustained efficacy for 12 months in its Phase 1 clinical trial.
Kangstem Biotech has reported that a single injection of its knee osteoarthritis treatment OSCA demonstrated sustained efficacy for 12 months in its Phase 1 clinical trial. Based on these results, we optimistic about the potential success of its ongoing Phase 2a trial.
we completed the 12-month long-term follow-up MRI evaluations from Phase 1 and received analysis results from imaging experts. The findings confirmed continued cartilage regeneration and recovery of the damaged subchondral bone in many patients in the mid- and high-dose groups. Notably, all participants in the high-dose group showed improvement across multiple parameters, including cartilage wear, abnormal structures, edema, synovitis, and meniscal damage. In addition, patients experienced a significant reduction in severe pain, resulting in a marked improvement in their quality of life.
The Head of Clinical Development at Kangstem Biotech stated, “Through this long-term follow-up, we have obtained data on pain relief, functional improvement, and structural regeneration including cartilage and subchondral bone 12 months after OSCA administration. We confirmed that the effects observed at the 6 month mark were maintained or even improved at 12 months. As a result, patient enrollment for the Phase 2a trial is progressing rapidly, with participants showing strong interest in continuing clinical trials. Moreover, demonstrating the long-term therapeutic efficacy of our Phase 1 trial allows us to present the kind of data sought by global markets and potential partners, which we believe will lead to significant business opportunities.”